Novartis announces updated analysis from Phase III NATALEE trial - TipRanks.com

Kisqal added to endocrine therapy in NATALEE trial reduces recurrence risk by 28.5% beyond three years in stage II/III HR+/HER2- early breast cancer, with consistent benefits across subgroups and secondary endpoints, including distant disease-free survival and a trend for improved overall survival.